Bundle care approach to reduce device associated infections in post-living-donor-liver transplantation in a tertiary care hospital, Egypt.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
05 Jul 2024
Historique:
received: 21 01 2024
accepted: 17 06 2024
medline: 6 7 2024
pubmed: 6 7 2024
entrez: 5 7 2024
Statut: epublish

Résumé

Device-associated infections (DAIs) are a significant cause of morbidity following living donor liver transplantation (LDLT). We aimed to assess the impact of bundled care on reducing rates of device-associated infections. We performed a before-and-after comparative study at a liver transplantation facility over a three-year period, spanning from January 2016 to December 2018. The study included a total of 57 patients who underwent LDLT. We investigated the implementation of a care bundle, which consists of multiple evidence-based procedures that are consistently performed as a unified unit. We divided our study into three phases and implemented a bundled care approach in the second phase. Rates of pneumonia related to ventilators [VAP], bloodstream infections associated with central line [CLABSI], and urinary tract infections associated with catheters [CAUTI] were assessed throughout the study period. Bacterial identification and antibiotic susceptibility testing were performed using the automated Vitek-2 system. The comparison between different phases was assessed using the chi-square test or the Fisher exact test for qualitative values and the Kruskal-Wallis H test for quantitative values with non-normal distribution. In the baseline phase, the VAP rates were 73.5, the CAUTI rates were 47.2, and the CLABSI rates were 7.4 per one thousand device days (PDD). During the bundle care phase, the rates decreased to 33.3, 18.18, and 4.78. In the follow-up phase, the rates further decreased to 35.7%, 16.8%, and 2.7% PDD. The prevalence of Klebsiella pneumonia (37.5%) and Methicillin resistance Staph aureus (37.5%) in VAP were noted. The primary causative agent of CAUTI was Candida albicans, accounting for 33.3% of cases, whereas Coagulase-negative Staph was the predominant organism responsible for CLABSI, with a prevalence of 40%. This study demonstrates the effectiveness of utilizing the care bundle approach to reduce DAI in LDLT, especially in low socioeconomic countries with limited resources. By implementing a comprehensive set of evidence-based interventions, healthcare systems can effectively reduce the burden of DAI, enhance infection prevention strategies and improve patient outcomes in resource-constrained settings.

Sections du résumé

BACKGROUND BACKGROUND
Device-associated infections (DAIs) are a significant cause of morbidity following living donor liver transplantation (LDLT). We aimed to assess the impact of bundled care on reducing rates of device-associated infections.
METHODS METHODS
We performed a before-and-after comparative study at a liver transplantation facility over a three-year period, spanning from January 2016 to December 2018. The study included a total of 57 patients who underwent LDLT. We investigated the implementation of a care bundle, which consists of multiple evidence-based procedures that are consistently performed as a unified unit. We divided our study into three phases and implemented a bundled care approach in the second phase. Rates of pneumonia related to ventilators [VAP], bloodstream infections associated with central line [CLABSI], and urinary tract infections associated with catheters [CAUTI] were assessed throughout the study period. Bacterial identification and antibiotic susceptibility testing were performed using the automated Vitek-2 system. The comparison between different phases was assessed using the chi-square test or the Fisher exact test for qualitative values and the Kruskal-Wallis H test for quantitative values with non-normal distribution.
RESULTS RESULTS
In the baseline phase, the VAP rates were 73.5, the CAUTI rates were 47.2, and the CLABSI rates were 7.4 per one thousand device days (PDD). During the bundle care phase, the rates decreased to 33.3, 18.18, and 4.78. In the follow-up phase, the rates further decreased to 35.7%, 16.8%, and 2.7% PDD. The prevalence of Klebsiella pneumonia (37.5%) and Methicillin resistance Staph aureus (37.5%) in VAP were noted. The primary causative agent of CAUTI was Candida albicans, accounting for 33.3% of cases, whereas Coagulase-negative Staph was the predominant organism responsible for CLABSI, with a prevalence of 40%.
CONCLUSION CONCLUSIONS
This study demonstrates the effectiveness of utilizing the care bundle approach to reduce DAI in LDLT, especially in low socioeconomic countries with limited resources. By implementing a comprehensive set of evidence-based interventions, healthcare systems can effectively reduce the burden of DAI, enhance infection prevention strategies and improve patient outcomes in resource-constrained settings.

Identifiants

pubmed: 38969966
doi: 10.1186/s12879-024-09525-4
pii: 10.1186/s12879-024-09525-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

674

Informations de copyright

© 2024. The Author(s).

Références

Graziadei I, Zoller H, Fickert P, Schneeberger S, Finkenstedt A, Peck-Radosavljevic M, et al. Indications for liver transplantation in adults. Wiener Klinische Wochenschrift. 2016;128(19–20):679–90. https://doi.org/10.1007/s00508-016-1046-1
doi: 10.1007/s00508-016-1046-1 pubmed: 27590261 pmcid: 5052293
El-Zanaty F, Way A. Egypt demographic and health survey 2008 (Egyptian Ministry of Health, El-Zanaty and Associates and Macro International, 2009). https://dhsprogram.com/publications/publication-fr220-dhs-final-reports.cfm Accessed 20 January 2024.
Wang Y, Gu Y, Huang F, Liu D, Zhang Z, Zhou N, et al. Risk factors for sepsis based on sepsis-3 criteria after orthotopic liver transplantation. Mediat Inflamm. 2018;2018:8703172–8. https://doi.org/10.1155/2018/8703172
doi: 10.1155/2018/8703172
Levitsky J, Goldberg D, Smith AR, Mansfield SA, Gillespie BW, Merion RM, Lok AS, Levy G, Kulik L, Abecassis M, Shaked A. Acute rejection increases risk of graft failure and death in recent liver transplant recipients. Clin Gastroenterol Hepatol. 2017;15(4):584–e5932. https://doi.org/10.1016/j.cgh.2016.07.035
doi: 10.1016/j.cgh.2016.07.035 pubmed: 27567694
Kumar NR, Balraj TA, Kempegowda SN, Prashant A. Multidrug-resistant sepsis: a critical healthcare challenge. Antibiotics. 2024;13(1):46. https://doi.org/10.3390/antibiotics13010046
doi: 10.3390/antibiotics13010046 pubmed: 38247605 pmcid: 10812490
Pouladfar G, Jafarpour Z, Malek Hosseini SA, Firoozifar M, Rasekh R, Khosravifard L. Bacterial infections in pediatric patients during early post liver transplant period: a prospective study in Iran. Transpl Infect Dis. 2019;21(1):e13001. https://doi.org/10.1111/tid.13001
doi: 10.1111/tid.13001 pubmed: 30221820
Prakash SS, Rajshekar D, Cherian A, Sastry AS. Care bundle approach to reduce device-associated infections in a tertiary care teaching hospital, South India. J Lab Physicians. 2017;9(4):273–8. https://doi.org/10.4103/JLP.JLP_162_16
Wassef M, Mukhtar A, Nabil A, Ezzelarab M, Ghaith D. Care bundle approach to reduce surgical site infections in acute surgical intensive care unit, Cairo, Egypt. Infect Drug Resist. 2020;13:229. https://doi.org/10.2147/IDR.S236814
doi: 10.2147/IDR.S236814 pubmed: 32095080 pmcid: 6995287
Horan T, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–32. https://doi.org/10.1016/j.ajic.2008.03.002
doi: 10.1016/j.ajic.2008.03.002 pubmed: 18538699
Rosenthal VD, Al-Abdely HM, El-Kholy AA, AlKhawaja SA, Leblebicioglu H, Mehta Y, et al. International nosocomial infection control consortium report, data summary of 50 countries for 2010–2015: device-associated module. Am J Infect Control. 2016;44(12):1495–504. https://doi.org/10.1016/j.ajic.2016.08.007
doi: 10.1016/j.ajic.2016.08.007 pubmed: 27742143
Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81. https://doi.org/10.1111/j.1469-0691.2011.03570.x
doi: 10.1111/j.1469-0691.2011.03570.x pubmed: 21793988
CLSI. Performance standards for antimicrobial susceptibility testing: 27th ed. Informational supplement M100-S27. Wayne, PA: Clinical and Laboratory Standards Institute. 2017.
Harbarth S, Sax H, Gastmeier P. The preventable proportion of nosocomial infections: an overview of published reports. J Hosp Infect. 2003;54(4):258–66. https://doi.org/10.1016/s0195-6701(03)00150-6 . quiz 321.
doi: 10.1016/s0195-6701(03)00150-6 pubmed: 12919755
Umscheid CA, Mitchell MD, Doshi JA, Agarwal R, Williams K, Brennan PJ. Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs. Infect Control Hosp Epidemiol. 2011;32(2):101–14. https://doi.org/10.1086/657912
doi: 10.1086/657912 pubmed: 21460463
Parekh JR, Greenstein S, Sudan DL, Grieco A, Cohen ME, Hall BL, et al. Beyond death and graft survival—variation in outcomes after liver transplant. Results from the NSQIP transplant beta phase. Am J Transplant. 2019;19(7):2108–15. https://doi.org/10.1111/ajt.15357
doi: 10.1111/ajt.15357 pubmed: 30887634
Schreiber PW, Sax H, Wolfensberger A, Clack L, Kuster SP, Swissnoso. The preventable proportion of healthcare-associated infections 2005–2016: systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2018;39(11):1277–95. https://doi.org/10.1017/ice.2018.183
doi: 10.1017/ice.2018.183 pubmed: 30234463
Russell TA, Fritschel E, Do J, Donovan M, Keckeisen M, Agopian VG, et al. Minimizing central line–associated bloodstream infections in a high-acuity liver transplant intensive care unit. Am J Infect Control. 2019;47(3):305–12. https://doi.org/10.1016/j.ajic.2018.08.006
doi: 10.1016/j.ajic.2018.08.006 pubmed: 30333081
Blot K, Bergs J, Vogelaers D, Blot S, Vandijck D. Prevention of central line-associated bloodstream infections through quality improvement interventions: a systematic review and meta-analysis. Clin Infect Dis. 2014;59(1):96–105. https://doi.org/10.1093/cid/ciu239
doi: 10.1093/cid/ciu239 pubmed: 24723276 pmcid: 4305144
Mukhtar A, Abdelaal A, Hussein M, Dabous H, Fawzy I, Obayah G, et al. Infection complications and pattern of bacterial resistance in living-donor liver transplantation: a multicenter epidemiologic study in Egypt. Transpl Proc. 2014;46:1444–7. https://doi.org/10.1016/j.transproceed.2014.02.022
doi: 10.1016/j.transproceed.2014.02.022
Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious diseases society of America. Clin Infect Dis. 2009;48:503–35. https://doi.org/10.1093/cid/civ933] . [PMID: 19191635.
doi: 10.1093/cid/civ933] pubmed: 19191635
Zhong L, Men TY, Li H, Peng ZH, Gu Y, Ding X, et al. Multidrug-resistant gram-negative bacterial infections after liver transplantation-spectrum and risk factors. J Infect. 2012;64:299–310. https://doi.org/10.1016/j.jinf.2011.12.005
doi: 10.1016/j.jinf.2011.12.005 pubmed: 22198738
Shi SH, Kong HS, Xu J, Zhang WJ, Jia CK, Wang WL, et al. Multidrug resistant gram-negative bacilli as predominant bacteremic pathogens in liver transplant recipients. Transpl Infect Dis. 2009;11:405–12. https://doi.org/10.1111/j.1399-3062.2009.00421.x
doi: 10.1111/j.1399-3062.2009.00421.x pubmed: 19638006
Freire MP, Soares Oshiro IC, Bonazzi PR, Guimaraes T, Ramos Figueira ER, Bacchella T, et al. Surgical site infections in liver transplant recipients in the model for end-stage liver disease era: an analysis of the epidemiology, risk factors, and outcomes. Liver Transpl. 2013;19(9):1011–9. https://doi.org/10.1002/lt.23682
doi: 10.1002/lt.23682 pubmed: 23744748
Montasser MF, Abdelkader NA, Abdelhakam SM, Dabbous H, Montasser IF, Massoud YM, Abdelmoaty W, Saleh SA, Bahaa M, Said H, El-Meteini M. Bacterial infections post-living-donor liver transplantation in Egyptian hepatitis C virus-cirrhotic patients: a single-center study. World J Hepatol. 2017;9(20):896–904. https://doi.org/10.4254/wjh.v9.i20.896 . PMID: 28804572; PMCID: PMC5534364.
doi: 10.4254/wjh.v9.i20.896 pubmed: 28804572 pmcid: 5534364
Yousef RH, Salem MR, Mahmoud AT. Impact of implementation of a modified World Health Organization multimodal hand hygiene strategy in a university teaching hospital. Am J Infect Control. 2020;48(3):249–54. https://doi.org/10.1016/j.ajic.2019.07.019
doi: 10.1016/j.ajic.2019.07.019 pubmed: 31601445
Al-Faouri I, Okour SH, Alakour NA, Alrabadi N. Knowledge and compliance with standard precautions among registered nurses: a cross-sectional study. Ann Med Surg (Lond). 2021;62:419–24. https://doi.org/10.1016/j.amsu.2021.01.058
doi: 10.1016/j.amsu.2021.01.058 pubmed: 33552505
Galal YS, Labib JR, Abouelhamd WA. Impact of an infection-control program on nurses’ knowledge and attitude in pediatric intensive care units at Cairo University hospitals. J Egypt Public Health Assoc. 2014;89(1):22–8. https://doi.org/10.1097/01.EPX.0000444562.71691.06
doi: 10.1097/01.EPX.0000444562.71691.06 pubmed: 24717397
Gupta P, Thomas M, Patel A, et al. Bundle approach used to achieve zero central line-associated bloodstream infections in an adult coronary intensive care unit. BMJ Open Qual. 2021;10:e001200. https://doi.org/10.1136/bmjoq-2020-001200
doi: 10.1136/bmjoq-2020-001200 pubmed: 33597274 pmcid: 7893645
Rosenthal VD, Yin R, Nercelles P, Rivera-Molina SE et al. International nosocomial infection control consortium (INICC) report of health care associated infections, data summary of 45 countries for 2015 to 2020, adult and pediatric units, device-associated module. Am J Infect Control. 2024;6:S0196-6553(23)00879-9. https://doi.org/10.1016/j.ajic.2023.12.019
Dukes KC, Reisinger HS, Schweizer M, Ward MA, Chapin L, Ryken TC, Perl TM, Herwaldt LA. Examining barriers to implementing a surgical-site infection bundle. Infect Control Hosp Epidemiol. 2024;45(1):13–20. https://doi.org/10.1017/ice.2023.114 . Epub 2023 Jul 26. PMID: 37493031; PMCID: PMC10782202.
doi: 10.1017/ice.2023.114 pubmed: 37493031

Auteurs

Mona A Wassef (MA)

Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Al-Saray Street, Al-Manial, Cairo, 11559, Egypt.

Doaa M Ghaith (DM)

Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Al-Saray Street, Al-Manial, Cairo, 11559, Egypt. doaaghaith@gmail.com.

Marwa M Hussien (MM)

Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Al-Saray Street, Al-Manial, Cairo, 11559, Egypt.

Mostafa A El-Shazly (MA)

General surgery and liver transplantation, Faculty of Medicine, Cairo University, Cairo, Egypt.

Reham H A Yousef (RHA)

Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Al-Saray Street, Al-Manial, Cairo, 11559, Egypt.
Microbiology, Immunology and Infectious Disease Department, College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH